Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review details the skin and hematological toxicities of tyrosine kinase inhibitors like erlotinib, gefitinib, and imatinib, and highlights ongoing concerns about cardiac toxicity, reporting no new clinical findings.

This study found that in thin cutaneous melanomas, tumor regression is associated with a higher risk of sentinel lymph node involvement.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

This case report describes the first instance of classical lichen planopilaris with atrophic lichenoid plaques developing in a Blaschko-linear pattern due to imatinib treatment in a patient with chronic myeloid leukemia.

This study describes that 65% of patients receiving imatinib mesylate in a patient assistance program experienced skin hypopigmentation, primarily in ethnically Chinese individuals, suggesting variability across populations.

This review covers skin manifestations in chronic kidney disease, highlighting their impact on quality of life, associated prognostic indicators, and available treatments, but provides no new clinical results.

This article discusses the various skin side effects associated with targeted cancer therapies like tyrosine kinase inhibitors and EGF-R inhibitors but provides no new clinical findings.

This study found that 95% of untreated advanced-stage follicular lymphoma patients responded to a single course of the Bexxar regimen, with 75% achieving complete remission and remaining disease-free for years.

This study found that hair depigmentation in mice and humans can be a dynamic indicator of KIT inhibition by the drug SU11248, correlating with treatment periods.

This study reported that among 10 tested 2-(4-chlorophenyl)-5-aryl-1,3,4-oxadiazole compounds, compound 4c showed the highest activity against cancer cell lines, with a 95.37% average growth rate.

This article is a letter to the editor discussing hair graying and loss potentially induced by imatinib mesylate, but it does not provide new research results.

This review discusses skin-related toxicities associated with targeted cancer therapies and emphasizes the need for dermatologists to understand and manage these adverse effects, but reports no new experimental results.

This review discusses various therapeutic strategies targeting platelet-derived growth factor signaling in diseases like cancer and atherosclerosis, and evaluates existing treatments without presenting new clinical data.

This review discusses treatments for chemotherapy-induced alopecia, highlighting scalp cooling for hair loss prevention and 2% topical minoxidil for regrowth acceleration as effective options, but reports a need for more rigorous trials to validate promising new therapies.

This review discusses the skin side effects associated with targeted cancer therapies and reports no new clinical results; it emphasizes the need for empirical management based on expert opinion.

This study observed that two patients treated with interferon α-2b and ribavirin for chronic hepatitis C experienced complete and reversible straightening of their natural curly hair, which recurred with treatment resumption.

This review discusses recent developments in targeted melanoma therapies, including BRAF/MEK/ERK pathway inhibitors and challenges like resistance and skin toxicities, but reports no new clinical results.

This study reported that FDG PET/CT imaging provided additional information that significantly impacted the treatment and prognosis in seven out of ten canine cancer patients, suggesting its potential in veterinary oncology.

This review covers various skin-related adverse drug reactions and lists common drugs associated with these reactions but presents no new clinical findings.

This study attempts to classify histomorphologic reactions to drugs to aid in diagnosing drug eruptions, which are common in hospitalized patients but lack specific diagnostic features.

This study found that 86% of patients with follicular non-Hodgkin's lymphoma were alive and nearly two-thirds remained in complete remission eight years after initial treatment with the radioimmunotherapy drug Bexxar.

In this study, researchers evaluated drug-target interaction data from three major resources and developed a framework for drug repurposing, revealing associations between drug properties and therapeutic groups to aid in compound prioritization and predicting repositioning opportunities for existing drugs, particularly in cancer treatment.

Any drug can cause skin reactions, but antibiotics, NSAIDs, and psychotropic drugs are more common, with some reactions being life-threatening.

This synopsis reviews key dermatological advancements discussed at the British Association of Dermatologists meeting in 2011 and reports no new clinical results.

This chapter reviews the skin side effects associated with targeted cancer therapies and emphasizes the importance of collaboration between oncologists and dermatologists without reporting new results.

This review discusses medications used in dermatology, detailing their side effects and interactions, and reports no new clinical results.

FDG PET/CT can improve cancer treatment plans in dogs.

In 2002, various skin reactions were reported due to different drugs, including allergies, hair loss, skin lesions, and other skin conditions.

This article provides a reference guide for various dermatological terms, treatments, and conditions, but reports no new clinical findings.

This study found that betibeglogene autotemcel significantly improved transfusion independence in 89% of patients with transfusion-dependent beta-thalassemia, although the high cost and manufacturing challenges may limit widespread adoption.